Glancy Prongay & Murray Investigates Claims on Behalf of Insys Therapeutics, Inc. Investors

Glancy Prongay & Murray LLP (“GPM”) is investigating potential claims on behalf of investors of Insys Therapeutics, Inc. ("Insys" or the "Company") (NASDAQ: INSY) concerning the Company and its officers’ possible violations of federal securities laws in connection with the alleged off-label marketing of Subsys.

The investigation concerns whether the Company was engaged in the illegal and improper off-labeling marketing of its product Subsys; and, whether certain Insys employees—including former Insys President and Chief Executive Officer, Michael L. Babich—were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys.

On April 24, 2015, the Southern Investigating Report Foundation ("SIRF") released an article entitled "Insys Therapeutics and the New 'Killing It,'" which reported that many patients being treated with the Company's Subsys product had died or were suffering from injuries connected to Subsys. On this news, the Company’s stock fell approximately $6.00 per share.

Then on December 3, 2015, SIRF published another article pertaining to Insys entitled "Murder Incorporated: Insys Therapeutics, Part I". In their report SIRF asserted that the Company operated a deceptive scheme in order to bolster the illegal off-label marketing and sale of Subsys. On this news, shares of Insys fell approximately $5.93 per share.

On January 25, 2016, SIRF published a third article concerning the Company and its misconduct, entitled "The Brotherhood of Thieves: Insys Therapeutics". This report shed more light on the off-label marketing scandal by asserting that Insys executives had been pressuring employees to promote the off-label marketing and sale of Subsys. Upon this news, the Company stock fell an additional $1.07 per share.

If you purchased Insys securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160209005221/en/